亿帆医药：易黄汤颗粒境内生产药品注册上市许可申请获受理

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice for the domestic production drug registration application for Yihuang Decoction Granules from the National Medical Products Administration on January 6, 2026 [1] Group 1 - The company has received regulatory approval for a new product, indicating progress in its product pipeline [1] - The acceptance notice is a significant step towards the commercialization of Yihuang Decoction Granules [1] - This development may enhance the company's market position in the pharmaceutical industry [1]